Mirikizumab Demonstrates Long-Term Efficacy on Histological Resolution in the Phase 3, Multicenter, Open-Label VIVID-2 Extension Study
Zeitschrift für Gastroenterologie | June 8, 2026 | Volume: 64 | Issue: 05 | Pages: e139-e140
10.1055/s-0046-1823082